Patient Medication Guide Essay Assignment Paper
Assignment: Patient Medication Guide – Zyprexa (Olanzapine)
Generic name of the drug: Olanzapine
Brand names: Zyprexa, Zyprexa Relprevv, and Zyprexa Zydis.
Classification:
Olanzapine is a second-generation or atypical antipsychotic medication. Patient Medication Guide Essay Assignment Paper
Food and Drug Administration (FDA) Approved Uses:
Off-label Uses of Olanzapine:
Medication Mechanism of Action:
The drug acts primarily on dopamine and serotonin receptors as an antagonist. It is an antagonist at dopamine 2 (D2) receptors in the mesolimbic pathway, inhibiting the actions of dopamine in the post-synaptic receptor (Thomas & Saadabadi, 2023). However, its interaction with D2 receptors is loose, making the drug dissociate easily from the receptor, thus allowing for normal dopamine neurotransmission (Thomas & Saadabadi, 2023). Its action on D2 receptors leads to a reduction in the positive symptoms of schizophrenia, such as delusions, hallucinations, disorganized thought, speech, and behavior (Thomas & Saadabadi, 2023). The medication also acts as an antagonist on serotonin 2A (5HT2A) receptors in the frontal cortex, leading to a decrease in the patient’s negative symptoms of schizophrenia, such as anhedonia, alogia, inattention, avolition, and flat affect (Thomas & Saadabadi, 2023). Its ability to reduce the negative symptoms of schizophrenia increases the drug’s likeability as a medication of choice for the treatment of schizophrenia.
Pharmacokinetics:
Absorption: The drug is administered daily with peak concentrations 6 hours following oral administration and 15 to 45 minutes following intramuscular administration. The drug takes almost a week or seven days to reach a steady state and has an average half-life of 30 hours (20 to 54 hours) (Thomas & Saadabadi, 2023)Patient Medication Guide Essay Assignment Paper.
Half-life definition: Half-life refers to the time that it takes for half of the drug in circulation to be eliminated from the body. In other words, elimination half-life refers to the time required for the concentration of a particular drug to decrease to half of its starting dose in the body (Hallare & Gerriets, 2023). Understanding the half-life determines a drug’s excretion rate and steady-state concentrations (Hallare & Gerriets, 2023). The half-life of drugs helps to dictate the dosing frequencies for medications to ensure steady-state concentrations and, hence, continued effects of the medication.
Distribution: Olanzapine’s volume of distribution is about 1000 liters, and it is distributed widely in the body (Thomas & Saadabadi, 2023). In plasma, it is transported throughout the body bound to albumin and alpha-1 acid glycoprotein (Thomas & Saadabadi, 2023). The drug is transported 93% bound to plasma proteins, leading to a longer duration of action and, hence, a longer elimination half-life.
Metabolism: The medication is extensively metabolized by the liver through glucuronidation and by the cytochrome P450 system largely by CYP1A2 enzyme and to a lesser extent by CYP2D6 enzyme (Thomas & Saadabadi, 2023). Genetic polymorphisms affecting the two cytochrome P450 enzymes that affect the drug’s metabolism do not affect its metabolism.
Excretion: The drug is extracted primarily in urine through the kidneys for 57% of the drug dose and through feces for 30% of the medication (Thomas & Saadabadi, 2023)Patient Medication Guide Essay Assignment Paper.
Pharmacodynamics:
Available Formulations:
The medication is available in tablet and injectable dosages that serve a variety of patients affected by schizophrenia and bipolar I disorder in manic episodes. For the agitated patient who is incapable of taking oral formulations, olanzapine can be administered as an intramuscular injection form drug formulations containing 5mg of olanzapine in 1 mL of injection solution. Oral medication is used in patients who can be compliant with taking the medication orally, and the drug is available in 2.5 mg, 5 mg, 7.5 mg, 10mg, 15 mg, and 20 mg tablets (Thomas & Saadabadi, 2023).
Appropriate Dosing:
In schizophrenia, the medication is administered 5 to 10 mg per day as the starting dose and increased by 5 mg per day at intervals of more than a week (Medscape, n.d.). The maintenance dose of the medication is 10 to 20 mg per day, and the daily dosing should not exceed 20 mg per day (Medscape, n.d.). The intramuscular dosing frequency differs depending on the oral maintenance dose administered to the patient, as a patient taking 20mg per day PO olanzapine will receive an intramuscular (IM) extended-release dose of 300 mg IM every two weeks for 8 weeks, then 300 mg IM every two weeks as opposed to 210 mg IM every 2 weeks or 405 mg IM every four weeks for the first 8 weeks then 150 mg every two weeks or 300 mg every four weeks for patients receiving 10 mg PO (Medscape, n.d.)Patient Medication Guide Essay Assignment Paper.
Bipolar Mania: Monotherapy is given 10 to 15 mg per day PO initially with increments of 5 mg per day every two days. As an adjunct treatment to lithium or sodium valproate, it is given 10mg per day PO. The maintenance dose in bipolar is 5 to 20 mg per day PO (Medscape, n.d.).
Agitation associated with schizophrenia and bipolar mania: Administer IM short-acting olanzapine at 2.5 to 10 mg per dose, with additional doses up to 10 mg two hours after the first dose and four hours after the second dose, not exceeding 30 mg per day (Medscape, n.d.).
Bipolar Depression: In combination with fluoxetine at 5 mg PO in the evening (Medscape, n.d.).
Chemotherapy-associated nausea or vomiting (off-label): Prophylaxis in combination with a serotonin 3 (5HT3) receptor antagonist and dexamethasone at 5 to 10 mg PO daily for three days (Medscape, n.d.).
Considerations for Dosing Alterations:
No dosing alterations are required for renal or hepatic impairment. However, among smokers or tobacco users, there is a need for a 30% increase in the daily dose, given the heightened drug metabolism caused by CYP1A2 induction in smokers (Keepers et al., 2020).
Considerations of use and dosing in Specific Populations:
Children: Not indicated for use in children below 13 years for treatment of schizophrenia or below 10 years in combination with fluoxetine for treatment of depressive episodes in bipolar I disorder.
Elderly: The drug should NOT be used in elderly patients with dementia-related psychosis for risk of increased mortality from increased risk of heart failure, sudden death due to cardiac disease, and pneumonia (Thomas & Saadabadi, 2023)Patient Medication Guide Essay Assignment Paper.
Pregnancy: Evidence of reported extrapyramidal symptoms, feeding disorders, and respiratory distress in neonates exposed to olanzapine during the third trimester (Thomas & Saadabadi, 2023). There is a need to monitor neonates for these adverse effects of the medication.
Breastfeeding: Olanzapine is the preferred agent during breastfeeding due to its low concentrations in human milk and breastfed infants. The primary adverse effect of concern is sedation in the infant (Thomas & Saadabadi, 2023).
Side Effects/Adverse Reactions Potential:
Clinical concerns with EPS and Tardive Dyskinesia:
Olanzapine’s D2 receptor blockage directly leads to an increased risk of akathisia, tardive dyskinesia, extrapyramidal symptoms, and neuroleptic malignant syndrome (Thomas & Saadabadi, 2023). However, the drug’s lower affinity and ease of dissociation from D2 receptors produce a lower risk for EPS compared to first-generation antipsychotics (Thomas & Saadabadi, 2023)Patient Medication Guide Essay Assignment Paper.
Contraindications:
Overdose considerations:
The therapeutic window of olanzapine is 20 ng/mL to 40 ng/mL (Thomas & Saadabadi, 2023). At 80 ng/mL, adverse effects occur, and the drug is lethal only when used with other medications, such as benzodiazepines (Thomas & Saadabadi, 2023). The drug becomes toxic at serum concentrations above 0.1 mg/L and is fatal at serum concentrations of more than 1 mg/L (Thomas & Saadabadi, 2023).
Diagnostics and Labs Monitoring:
Other Considerations:
Pertinent Patient Education Considerations:
The patient should report immediately to the healthcare setting if these symptoms develop after taking olanzapine.
References
Hallare, J., & Gerriets, V. (2023). Half-life. Treasure Island (FL): Patient Medication Guide Essay Assignment Paper StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554498/
Keepers, A. G., Fochtmann, J. L., Anzia, M. J., Benjamin, S., Lyness, M. J., Mojtabai, R., Servis, M., Walaszek, A., Buckley, P., Lenzenweger, F. M., Young, S. A., Degenhardt, A., & Hong, S. (2020). The American Psychiatric Association practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry, 177(9), 868-872. https://doi.org/10.1176/appi.ajp.2020.177901
Medscape (n.d.). Olanzapine (Rx). Medscape. https://reference.medscape.com/drug/zyprexa-relprevv-olanzapine-342979
Thomas, K., & Saadabadi, A. (2023). Olanzapine. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532903/ Patient Medication Guide Essay Assignment Paper
NURS 6630N WEEK 7 ASSIGNMENT INSTRUCTIONS
This week, you will create a Medication Study Guide to share with your peers. This guide is intended to be a useful learning tool for you to use as you prepare for your clinical courses.
Use Zyprexa (Olanzapine) or one below
Clozapine | Iloperidone | |||
Paliperidone | Quetiapine | Risperidone | Ziprasidone | Lurasidone |
TO PREPARE FOR THIS ASSIGNMENT:
THE ASSIGNMENT
Create a 3- to 4-page (excluding visual elements) Medication Study Guide for your assigned psychotropic medication agents that may be utilized by you and colleagues for study. Your medication guide should be in the form of an outline and should include a title page, citations, and references. You should incorporate visual elements, such as concept maps, charts, diagrams, images, color coding, mnemonics, and/or flashcards. Be creative!
Note: Your Medication Study Guide should not be in the format of an APA paper.
Also Note: Your guide should be informed by the FDA-Approved and Evidenced-Based, Clinical Practice Guidelines Research.
Areas of importance that you should address—but are not limited to—include: Patient Medication Guide Essay Assignment Paper
Support your rationale with a minimum of three (3) academic resources.
Note: While you may use the course text to support your rationale, it will not count toward the resource requirement. You should be utilizing primary and secondary literature. Patient Medication Guide Essay Assignment Paper
LEARNING RESOURCES:
Chlorpromazine | Fluphenazine | Haloperidol | Loxapine | Perphenazine |
Aripiprazole | Asenapine | Clozapine | Iloperidone | Olanzapine |
Paliperidone | Quetiapine | Risperidone | Ziprasidone | Lurasidone |
Brexpiprazole | Cariprazine | Lumateperone | Benztropine | Propranolol |
Deutetrabenazine | Valbenazine |
You will need to submit your Assignment to two places:
NOTE BELOW:
Students who use subheadings/paragraphs in their posts get better grades.
PLEASE USE SUBHEADINGS/PARAGRAGHS
NURS_6630_Week7_Assignment_Rubric
NURS_6630_Week7_Assignment_Rubric | ||||||
Criteria | Ratings | Pts | ||||
This criterion is linked to a Learning OutcomeMedication guide includes brand and generic names, FDA uses, classification, mechanism of action, pharmacokinetics and pharmacodynamics, dosing, administration, considerations for alternate dosing, considerations for prescribing specialty populations, definition of half-life, why half-life important, and what is the half-life for assigned medication, side effects/adverse reaction potentials, contraindications, overdose considerations, diagnostics/labs, and patient education consideration. |
|
50 pts | ||||
This criterion is linked to a Learning OutcomeMedication guide includes clinical concerns with EPS and Tardive Dyskinesia with screening tool to be utilized included. |
|
20 pts | ||||
This criterion is linked to a Learning OutcomeMedication guide includes legal, ethical and social considerations. |
|
10 pts | ||||
This criterion is linked to a Learning OutcomeThe study guide is properly formatted as an outline and includes visual elements for the appropriate audience. The guide is succinct and is 3–4 pages. Three evidence-based, peer-reviewed scholarly references outside of course resources were used. |
|
10 pts | ||||
This criterion is linked to a Learning OutcomeWritten Expression and Formatting—English writing standards: Correct grammar, mechanics, and proper punctuation |
|
5 pts | ||||
This criterion is linked to a Learning OutcomeWritten Expression and Formatting: The paper follows correct APA format for title page, citations, and reference list. |
|
5 pts |
Create a 3- to 4-page (excluding visual elements) Medication Study Guide for your assigned psychotropic medication agents that may be utilized by you and colleagues for study. Your medication guide should be in the form of an outline and should include a title page, citations, and references. You should incorporate visual elements, such as concept maps, charts, diagrams, images, color coding, mnemonics, and/or flashcards. Be creative!
Note: Your Medication Study Guide should not be in the format of an APA paper.
Also Note: Your guide should be informed by the FDA-Approved and Evidenced-Based, Clinical Practice Guidelines Research.
Areas of importance that you should address—but are not limited to—include:
• Title page
• Description of the psychopharmacological medication agent, including brand and generic names, as well as appropriate FDA indication uses
• Any supporting, valid, and reliable research for non-FDA uses
• Drug classification
• The medication mechanism of action
• The medication pharmacokinetics
• The medication pharmacodynamics
• Appropriate dosing, administration route, and any considerations for dosing alterations
• Considerations of use and dosing in specific specialty populations, such as children, adolescents, elderly, pregnant people, those exhibiting suicidal behaviors, etc.
• Definition of half-life, why half-life is important, and the half-life for your assigned medication
• Side effects/adverse reactions potential
• Discuss clinical concerns with EPS and Tardive Dyskinesia
Note: Be sure to include screening tools that would be utilized.
• Contraindications for use including significant drug to drug interactions
• Overdose considerations
• Diagnostics and labs monitoring comorbidities considerations
• Legal, ethical, and social considerations
• Pertinent patient education considerations
• References page
Support your rationale with a minimum of three (3) academic resources.
Note: While you may use the course text to support your rationale, it will not count toward the resource requirement. You should be utilizing primary and secondary literature.